2011 Scrip 100: Will Dilma be good for pharma?
This article was originally published in Scrip
Executive Summary
Luiz Inacio Lula da Silva (Lula) will step down as President of Brazil in January 2011 after steering his country into a new era of stability and prosperity. Now, as his protégé Dilma Rousseff prepares to take over, there is a wide expectation amongst those same commentators that she will continue the fiscally-responsible strategies of her mentor. Mark Hollis examines the likely implications for the pharmaceutical industry.
You may also be interested in...
1-2-300! The biosimilar horde stands at the gate
Despite claims from 'research-based' biologics manufacturers and their representatives in the EU and US that the biosimilars market is small and relatively unimportant, the age of biosimilars is clearly already upon us. A recently launched database from Datamonitor reveals a total of 556 biosimilars currently in development or being marketed globally with over 200 companies involved in the endeavour.
UK Budget good for large corporates and academia, but little for biotechs
The UK Chancellor of the Exchequer [finance minister] George Osborne assured Parliament on 21 March that he would be backing industries such as pharmaceuticals, amongst others, in an effort to reduce the dominance of the financial services industry.
Biosimilars regulation in emerging markets
Mark Hollis explores developments in emerging markets and considers what their impact might be on growth.